Summit Therapeutics' Partner Akeso Announces Overall Survival Results From The Randomized, Double-Blind Phase III HARMONi-2 Study Evaluating Ivonescimab Monotherapy; Ivonescimab Monotherapy Demonstrated A Statistically Significant Improvement Compared To Pembrolizumab Monotherapy.

뉴스 본문을 불러오고 있어요.

Summit Therapeutics' Partner Akeso Announces Overall Survival Results From The Randomized, Double-Blind Phase III HARMONi-2 Study Evaluating Ivonescimab Monotherapy; Ivonescimab Monotherapy Demonstrated A Statistically Significant Improvement Compared To Pembrolizumab Monotherapy. | 웨이프 WAPE

Summit Therapeutics' Partner Akeso Announces Overall Survival Results From The Randomized, Double-Blind Phase III HARMONi-2 Study Evaluating Ivonescimab Monotherapy; Ivonescimab Monotherapy Demonstrated A Statistically Significant Improvement Compared To Pembrolizumab Monotherapy.

기사 요약

관련 종목

댓글 —